Showing posts with label Mesothelioma. Show all posts
Showing posts with label Mesothelioma. Show all posts

The Mesothelioma Combat Guide for Veterans

Posted by Unknown | Posted in , , , | Posted on 10:05

0

The Mesothelioma Combat Guide for Veterans

Our nation’s veterans are the population most at risk for developing mesothelioma. Because asbestos exposure was unavoidable for many, mesothelioma is still one of the most deadly diseases that affect veterans even today.

For veterans concerned about their risk of asbestos exposure and mesothelioma, the Mesothelioma Cancer Alliance is here to help.

Find information on the exposure risks for each branch of service:

ArmyAir ForceMarinesNavy – the branch most known for developing mesothelioma, due to use of asbestos in naval ships and shipyards. To find out if you were exposed: Ships –Search the ship you worked on to learn if asbestos was present onboard.Shipyards –Search shipyards known for asbestos exposure during construction and repair of ships.Navy Battleship

I am serving/recently served in Iraq. Is this still an issue for me?

Iraq has no bans or regulations on asbestos use. It has been used in construction projects in recent years.If structures with asbestos are damaged, asbestos fibers can become airborne and put soldiers at risk of inhalation.

I think I may have been exposed to asbestos. What should I do now?

Visit a veteran treatment center if you feel you may have been exposed to asbestos or have been diagnosed with mesothelioma. There are also doctors and cancer centers that specialize in mesothelioma treatment; search the facilities and doctors in your area. If you have been diagnosed with mesothelioma or another asbestos related disease, you could be eligible for compensation from the responsible party/parties. Every case is different, but seeking legal support can help ease the burden of the financial stress a disease can bring.MCA Facebook Screenshot

Going through a cancer diagnosis is a life-changing event. The Mesothelioma Cancer Alliance is a unique and large community of victims and supporters who are willing to help.

Visit MCA’s Facebook page to connect with over 49,000 community members who can answer questions, share experiences, and offer their support.Visit the Mesothelioma Cancer Alliance Blog for valuable resources for cancer patients and caregivers, timely information about the disease, and stories of inspiration from other Mesothelioma Warriors.Tags: air force, army, cancer, facebook, legal support, marines, mesothelioma, mesothelioma and veterans, mesothelioma lawyer, mesothelioma treatment centers, navy, navy ships, navy shipyards, veteran treatment centers, veterans

< Older Builds cancer awareness through social media and bloggingPassionate about helping veterans learn about military service health risksAdvocate for holistic complementary therapies in cancer treatmentFocuses on the wellbeing of mind, body & spirit

Read more about Emily »

Google+Twitter


View the original article here

The Treatment Dilemma: Assessing Response in Malignant Pleural Mesothelioma

Posted by Unknown | Posted in , , , , , , | Posted on 07:27

0

Stethoscope

Among the many challenges of managing malignant pleural mesothelioma (MPM) is reliably assessing the response of the disease to our treatment. We don’t want to discard a treatment that is effective, nor do we want to have patients continue on a treatment that isn’t helpful but is causing significant side effects. In oncology, we typically grade our work by comparing an imaging study like a computerized tomography (CT) scan of the chest done after 2-3 cycles of systemic therapy (usually covering a 6-9 week interval) to a baseline scan performed prior to the start of treatment. As you’d suspect, significant tumor shrinkage is good, while growth is bad, and stable disease is somewhere in between. Typically, we want to continue our treatment in the absence of significant progression or prohibitive side effects.

So why is it so difficult to measure response in MPM? Unlike most solid tumors, MPM doesn’t typically appear on scans as a well circumscribed sphere that can be easily measured. Instead, it appears as a rind around the lung, often with irregular contours, sometimes areas of benign plaques from asbestos exposure, and collections of pleural fluid filling the cavity between the outside of the lung and the inner chest wall. Patients who have undergone a palliative pleurodesis, an intervention in which there is deliberate inflammation within the pleural space in order to cause scarring and close off that space (and thereby prevent fluid from filling there), will typically have marked thickening in that area that represents inflammation and scarring (the desired effect of the pleurodesis) that can be remarkably difficult to distinguish from active cancer.

There are various ways to contend with the challenges of measuring response to treatment for MPM. First, metabolic/functional imaging with positron emission tomography (PET) scanning along with fused CT images is often employed, as it can be instructive to see the level of metabolic activity decrease or increase as an indicator of response or progression, respectively, particularly when the thickness of the rind of tissue thought to represent MPM is not obviously increasing or decreasing in thickness. It is worth noting, however, that a pleurodesis is also expected to transiently increase PET activity in the pleural space in the weeks and perhaps even months after this procedure is performed, so it is necessary to be cautious about interpreting changes in PET uptake that have developed following a pleurodesis. Another clue can come from changes in a patient’s symptoms: many patients with MPM will experience chest wall pain from their underlying disease, and changes in a patient’s symptoms are another helpful indicator of the direction that the cancer is moving in when imaging is notoriously ambiguous. Finally, a blood test such as levels of soluble mesothelin-related proteins (MSRP) can potentially serve as a serum-based indicator that the cancer is responding or progressing.

Ideally, we would hope to have a test for assessing treatment response in MPM that is widely available and well validated. We are limited in the relative infrequency of the disease, with patients treated in a wide range of settings with varied levels of expertise in interpreting imaging results that are often ambiguous and complex. In this setting, it is often necessary to accept greater ambiguity, to be pleased to see an absence of convincing progression, and to utilize additional clues such as the trajectory of a patient’s cancer-related symptoms and potentially serum-based testing such as MSRP levels to provide greater direction as we do our best to make good judgments about the value of the treatment being administered.


View the original article here

Mesothelioma Research: Where 2012 Took Us, and What 2013 Has in Store

Posted by Unknown | Posted in , , , | Posted on 02:19

0

In a new year, it’s traditional to review recent achievements, then identify goals for the year that lies ahead.

In the December 2012 issue of the Journal of Thoracic Oncology, mesothelioma expert Anne Tsao analyzed the recent – and upcoming – directions in mesothelioma research. The article focused on three main areas of development: anti-angiogenic drugs, immunotherapy and biomarkers.

These treatments have been in development long before 2012 – but researchers did make several breakthroughs in each of the fields. Experts with the Southwest Oncology Group, the Memorial Sloan-Kettering Cancer Center and similar research organizations plan to take these findings to the next level, thanks to funds from the Department of Defense and national cancer research groups.

While summarizing the year’s clinical trial activity, Dr. Jessica Donington noted an emphasis on anti-angiogenic agents, or drugs that prevent tumors from creating new blood vessels (which allows the tumor to spread from its origin). Researchers are finding great promise in these drugs for mesothelioma patients who meet a very specific set of characteristics. These trials have produced positive responses for sunitinib, bevacizumab/gemcitabine/platinum-based chemotherapy regimens, and the tumor-specific peptide known as NGR-hTNF.

Moving Forward

Researchers have already identified vorinostat as a potential treatment for mesothelioma. This lymphoma drug has produced median survival rates of up to four weeks longer than placebo drugs, but further developmental trials are currently on pause. Once researchers can provide further analysis on the biomarkers that indicate a positive response to vorinostat, they may be able to launch additional studies.

Donington also mentioned a clinical trial that is currently wrapping up at MD Anderson Cancer Center. The study is one of the first efforts to incorporate pre- and post-treatment biopsies, personalized treatment plans and a novel targeted agent.

Dr. Ibrahim discussed relevant developments in immunotherapy, many of which focused on the use of tremelimumab. This human antibody is proving especially useful in patients who do not respond to traditional chemotherapy drugs. In one study of 22 patients, tremelimumab produced two partial responses, stabilized four patients’ progression and yielded an overall survival of 17.5 months.

Moving forward

In light of the recently completed phase II immunotherapy studies, researchers hope to advance to the next stage in tremelimumab testing. If certain results are achieved, the drug may become an ideal “salvage therapy” for mesothelioma patients who do not respond to first-line treatment.

Dr. Anne Tsao concluded the article with an overview of biomarker research. In the last year, this research has included studies of genetic mutations, serum markers, blood-based markers and prognostic tumor markers. Most recently, researchers identified the biomarker, BAP1, which may contribute to patients’ genetic predisposition for non-asbestos-related mesothelioma.

Moving forward

The MD Anderson Cancer Center and the Memorial Sloan-Kettering Cancer Center will soon open enrollment for a WT-1 vaccine trial. This vaccine may prompt attacks on mesothelioma cells contaning the WT-1 biomarker.

Researchers also hope to identify a more accurate prognostic biomarker for mesothelioma. While one team in Boston has identified a four-gene ration test that has decent results, they must adapt the test to account for several limitations (including the lack of real-time results).

These advancements may certainly change the way doctors currently treat mesothelioma. Each trial brings us one step closer to an effective treatment – which the mesothelioma community will pursue this year, and each year that follows, until we find a cure.

faith Faith Franz is a content writer for the Mesothelioma Center. She joined the team in January 2011 to help mesothelioma patients empower themselves through knowledge about their diagnosis. Twitter Facebook Reddit Delicious Stumbleupon

View the original article here

Mesothelioma Cancer Patients Hurt by Court Ruling Against Medicinal Marijuana

Posted by Unknown | Posted in , , , , , , , | Posted on 02:14

0

Mesothelioma cancer patients utilizing marijuana for medicinal purposes were dealt a setback earlier this month when a federal appeals court in Washington D.C. ruled in favor of the government’s long-standing classification of cannabis as a top-tier, dangerous drug.

The ruling dismissed a challenge to the Drug Enforcement Agency’s refusal to reclassify marijuana and loosen the restrictions that mostly prohibit the production, sale and use of it.

Many cancer patients have been using marijuana to combat the nausea and appetite loss that typically comes with chemotherapy treatments – and to help with pain management –, but the appeals court still sided with the DEA, making it much more difficult to obtain legally.

Although voters or legislators in 18 states have enacted laws in recent years making medicinal marijuana legal (under strict controls) – and two states have legalized it for recreational use – the federal designation remains unchanged after the court ruling.

The DEA, under the Controlled Substance Act of 1970, still classifies marijuana as a Schedule 1 drug, with no accepted medical uses, placing it alongside heroin and LSD.

“To establish accepted medical use, the effectiveness of a drug must be established in well-controlled, well-designed, well-conducted and well-documented scientific studies with a large number of patients. To date, such studies have not been performed,” the DEA stated in defense of its decision, which was used in the appeals court opinion.

Americans for Safe Access, a marijuana advocacy group, and several disabled American veterans, brought the case in October 2012 before a three-judge panel.  The DEA has rejected a similar petition in 2011.

More than 200 published studies were cited by Americans for Safe Access – including one by the Institute of Medicine (IOM), a governmental health advisor – to demonstrate the medical efficacy of marijuana, but the overall reasoning was rejected by the court.

“The IOM report does indeed suggest that marijuana might have medicinal benefits. However, the DEA fairly construed this report as calling for ‘more and better studies to determine potential medical applications of marijuana,’ and not as sufficient proof of medical efficacy itself,” the court opinion read.

The Americans for Safe Access has organized a conference called Bridging the Gap between Public and Policy, for Washington, D.C. on Feb. 25. It will include a Congressional lobbying effort that day.

The chief counsel for the ASA already has said it will seek another hearing before the full, nine-person appeals court, and a possible appeal to the United States Supreme Court on the matter.

“We’re disappointed, but not surprised,” Steph Sherer, ASA executive director, told the Los Angeles Times of the recent ruling. Sherer told the Times that more than one million patients have used marijuana for medicinal purposes.

The use of medicinal marijuana in Western countries can be traced back to the 19th century when it was used to relieve inflammation and pain. It was shown to help with convulsions and spasms, providing quick relief for a number of symptoms associated with physical ailments.

Mesothelioma patients in states where it is legal for medicinal purposes must have a prescription from a physician and a registration card to use the plant. The laws vary from state to state.

Although smoking marijuana provides the quickest relief from pain, patients already with lung problems can consume it through the digestive process by eating it in baked goods. Drug companies also have developed synthetic versions that can be taken in pill form.

Patients in various trials have reported its usefulness in improving sleep quality and increasing appetite, which are common problems with cancer patients. It also has helped with nausea, pain and anxiety relief. Additionally, it has shown to have fewer lasting side effects compared to many opiates that are prescribed to cancer patients by doctors.

TimPovtak An award winning reporter and writer, Tim Povtak is a senior content writer for the Mesothelioma Center. He previously worked at the Orlando Sentinel and then at AOL. You can contact him directly tpovtak@asbestos.com with any story ideas or comments. Twitter Facebook Reddit Delicious Stumbleupon

View the original article here

Mesothelioma Cancer Patients Hurt by Court Ruling Against Medicinal Marijuana

Posted by Unknown | Posted in , , , , , , , | Posted on 02:13

0

Mesothelioma cancer patients utilizing marijuana for medicinal purposes were dealt a setback earlier this month when a federal appeals court in Washington D.C. ruled in favor of the government’s long-standing classification of cannabis as a top-tier, dangerous drug.

The ruling dismissed a challenge to the Drug Enforcement Agency’s refusal to reclassify marijuana and loosen the restrictions that mostly prohibit the production, sale and use of it.

Many cancer patients have been using marijuana to combat the nausea and appetite loss that typically comes with chemotherapy treatments – and to help with pain management –, but the appeals court still sided with the DEA, making it much more difficult to obtain legally.

Although voters or legislators in 18 states have enacted laws in recent years making medicinal marijuana legal (under strict controls) – and two states have legalized it for recreational use – the federal designation remains unchanged after the court ruling.

The DEA, under the Controlled Substance Act of 1970, still classifies marijuana as a Schedule 1 drug, with no accepted medical uses, placing it alongside heroin and LSD.

“To establish accepted medical use, the effectiveness of a drug must be established in well-controlled, well-designed, well-conducted and well-documented scientific studies with a large number of patients. To date, such studies have not been performed,” the DEA stated in defense of its decision, which was used in the appeals court opinion.

Americans for Safe Access, a marijuana advocacy group, and several disabled American veterans, brought the case in October 2012 before a three-judge panel.  The DEA has rejected a similar petition in 2011.

More than 200 published studies were cited by Americans for Safe Access – including one by the Institute of Medicine (IOM), a governmental health advisor – to demonstrate the medical efficacy of marijuana, but the overall reasoning was rejected by the court.

“The IOM report does indeed suggest that marijuana might have medicinal benefits. However, the DEA fairly construed this report as calling for ‘more and better studies to determine potential medical applications of marijuana,’ and not as sufficient proof of medical efficacy itself,” the court opinion read.

The Americans for Safe Access has organized a conference called Bridging the Gap between Public and Policy, for Washington, D.C. on Feb. 25. It will include a Congressional lobbying effort that day.

The chief counsel for the ASA already has said it will seek another hearing before the full, nine-person appeals court, and a possible appeal to the United States Supreme Court on the matter.

“We’re disappointed, but not surprised,” Steph Sherer, ASA executive director, told the Los Angeles Times of the recent ruling. Sherer told the Times that more than one million patients have used marijuana for medicinal purposes.

The use of medicinal marijuana in Western countries can be traced back to the 19th century when it was used to relieve inflammation and pain. It was shown to help with convulsions and spasms, providing quick relief for a number of symptoms associated with physical ailments.

Mesothelioma patients in states where it is legal for medicinal purposes must have a prescription from a physician and a registration card to use the plant. The laws vary from state to state.

Although smoking marijuana provides the quickest relief from pain, patients already with lung problems can consume it through the digestive process by eating it in baked goods. Drug companies also have developed synthetic versions that can be taken in pill form.

Patients in various trials have reported its usefulness in improving sleep quality and increasing appetite, which are common problems with cancer patients. It also has helped with nausea, pain and anxiety relief. Additionally, it has shown to have fewer lasting side effects compared to many opiates that are prescribed to cancer patients by doctors.

TimPovtak An award winning reporter and writer, Tim Povtak is a senior content writer for the Mesothelioma Center. He previously worked at the Orlando Sentinel and then at AOL. You can contact him directly tpovtak@asbestos.com with any story ideas or comments. Twitter Facebook Reddit Delicious Stumbleupon

View the original article here

World Cancer Day Brings Global Perspective to Fight against Mesothelioma

Posted by Unknown | Posted in , , , , , , , | Posted on 02:08

0

The Mesothelioma Center at Asbestos.com is among the many organizations today that are observing World Cancer Day 2013, demonstrating the growing importance of advocacy in a global fight against this dreaded disease.

Today’s World Cancer Day is an initiative of the Union for International Cancer Control (UICC), which announced Monday its latest goal of preventing 1.5 million deaths annually from the disease.

The UICC, which is based in Geneva, Switzerland, estimates that 7.6 million people worldwide die each year from cancer. It also believes that one-third of those deaths are preventable.

Although a recent report by the American Cancer Society detailed a slow but steady decline in cancer rates in the United States, the UICC believes that current rates on a global scale will double within the next 20 to 40 years without the proper measures in place.

“There is need for a global commitment to help drive advancements in policy and encourage implementation of comprehensive cancer control plans,” said Christopher Wild, M.D., director of the International Agency for Research on Cancer. “We have a collective responsibility to support low and middle income countries that are tackling a cancer epidemic with insufficient resources.”

Asbestos-related diseases, which kill an estimated 100,000 people each year, are expected to increase in many of those still-developing countries. Among the diseases are mesothelioma, a slow-developing cancer that attacks the lining around the lungs and other vital organs.

Asbestos, a naturally occurring mineral, has been banned in more than 50 countries, but its use has increased in others because of its versatility, affordability and heat-resistant qualities that still make it desirable for commercial use.

The UICC considers asbestos as one of its top cancer-causing, workplace hazards. And one of its goals of World Cancer Day is the continued emphasis on raising awareness toward preventable cancers like mesothelioma and the dangers from asbestos fibers.

There were 442 World Cancer Day Events scheduled globally for Feb. 4 and registered with the UICC, which includes 156 countries and many of the major cancer societies, research institutes and patient groups.

Various communities held events both big and small, including informational campaigns, seminars, film screenings and educational meetings involving simple things like healthier eating and trying to stop smoking.

In the United States, there were events scheduled from coast to coast. One of the most visible was in New York City, where the landmark Empire State Building was decorated and lit in blue and orange lights, reflecting the colors of the UICC.

As part of World Cancer Day, the UICC also adopted the World Health Organization’s (WHO)  “25 by 25? campaign. The goal is for a 25 percent reduction of premature cancer deaths by the year 2025. Based upon the projection of 6 million preventable cancer deaths that year, the UICC set its goal on that 1.5 million figure.

“This World Cancer Day, its members and partners urge everyone from individuals to governments to take a stand against damaging myths on cancers,” said UICC CEO Cary Adams. “By truly understanding this deadly disease, governments can develop appropriate strategies to reduce premature deaths.”

Adams pointed to four major myths (and truths behind them) that have held back the reduction of cancer:

Myth 1: Cancer is just a health issue. Truth: Cancer has wide-reaching, economic, social and human-rights implications.Myth 2: Cancer is a disease of the wealthy, elderly and developed countries. Truth: Cancer is a global epidemic, affecting everyone regardless of socio-economic standing, and with still-developing countries carrying a disproportionate burden.Myth 3: Cancer is a death sentence. Truth: Many cancers now can be cured and others can be treated effectively, allowing people to extend their lives significantly.Myth 4: Cancer is inevitable. Truth: At least 30 percent of cancers can be prevented with the right strategies and the current knowledge.TimPovtak An award winning reporter and writer, Tim Povtak is a senior content writer for the Mesothelioma Center. He previously worked at the Orlando Sentinel and then at AOL. You can contact him directly tpovtak@asbestos.com with any story ideas or comments. Twitter Facebook Reddit Delicious Stumbleupon

View the original article here

Could Fowlpox Vaccination Be Next Big Mesothelioma Treatment?

Posted by Unknown | Posted in , , , , | Posted on 02:07

0

Deepak Chopra, one of the world’s most acclaimed holistic physicians, once told followers: “Instead of thinking outside the box, get rid of it.”

Several mesothelioma therapies currently under investigation fall outside the box of conventional treatments. Cancer stem cell research, biomarker research and developments in gene therapy are inspiring an ever-increasing range of options beyond surgery, chemotherapy and radiation therapy.

But while those treatments fall outside the box, a new treatment destroys its boundaries.

The therapy? A fowlpox vaccination.

Yes, that fowlpox vaccination – the shot that farmers traditionally give chickens and turkeys to prevent viral outbreaks of contagious lesions.

Recently, researchers have found a way to take the vaccine from the farmyard to the cancer center – and with surprisingly encouraging results.

Pox viruses are considered some of the most ideal agents for targeted cancer treatment. The viruses are considered safe to modify into a vaccine that help the body’s own immune system kill off cancer cells.

The fowlpox virus is especially easy to modify. Lab workers can design it to enter healthy cells and deposit a set of specific proteins that can trigger an immune response.

Once inside the body, the vaccine may also generate additional white blood cells that can continue carrying out the mission.

This concept lies at the heart of a new study, conducted by researchers at the University of Hawaii.

The study, which will appear in a future issue of the International Journal of Cancer, tested a fowlpox vaccination that was adapted to contain the protein known as survivin.

Survivin is “a protein … that makes cancer cells resistant to chemotherapy,” the study’s lead researcher, Pietro Bertino, told Asbestos.com. The protein also regulates programmed cell death, a process known as apoptosis.

“My hypothesis was that, by survivin inhibition, all mechanisms that force the cancer cell to stay alive during chemotherapy could be turned off,” Bertino explained.

After he realized this protein could potentially play a major role in mesothelioma treatment, he had to find a way to get it into the body. An immunotherapy approach turned out to be the key. This is where the fowlpox vaccine comes in handy – it was the perfect vehicle to deliver the survivin to the tumors.

Bertino’s research team injected mice with malignant mesothelioma cells. They then provided a dose of the survivin-laced fowlpox vaccine. Some mice received the vaccine under the skin, while others received it directly into the peritoneum.

Both delivery methods produced a “significant immune response.” This response correlated with delayed tumor growth and improved overall survival. Better yet, none of the mice developed potentially serious side effects – like autoimmune conditions or infertility – after treatment.

Bertino’s team is now considering future directions for the vaccine.

“The fowlpox vaccine is our first attempt to induce an immune response against mesothelioma cells that can be used for both therapeutic and preventive purposes. We recently started collaborating with EpiVax … [and together] we identified a list of very immunogenic survivin peptides that should generate high responses in human subjects.”

When fully developed, this vaccine may have a distinct edge over other therapies.

“Successful immunotherapies have the advantage [of inducing] an immune response … that may persist years after vaccination. Chemotherapy, on the other hand, has an affect limited to a few days,” Bertino explained.

Because chemotherapy offers such a short response, patients have to participate in several cycles of the treatment.

“Repeating chemotherapy cycles usually induces high toxicity,” Bertino adds. The fowlpox vaccine could help patients avoid those serious side effects, which often include severe nausea and hair loss.

Certain vaccines also show more promising results than chemotherapy drugs, which rarely put mesothelioma into remission.

“With immunotherapy, our group induced complete tumor regression in animal models of mesothelioma. We never achieved a similar result in studies with chemotherapy.”

Since it is still in its animal testing phase, the fowlpox vaccine still has a long way to go before it is approved for human use. But Bertino feels that the promising results from his study can justify future clinical trials in due time.

As research teams continue to take the fowlpox vaccine to the next level, other vaccination options are already available through clinical trials.

In 2010, researchers tested a vaccine made from a patient’s own immune cells and tumor antigens. The trial – the first human trial of its kind – found that the vaccine could help “jump-start” the immune system’s response to the tumors.

Early last year, a UK-based research group announced another vaccination trial, this time for the TroVax® shot. Once the study officially begins, the researchers will see if this virus-based vaccine can stimulate the immune system to attack cancerous cells.

Our clinical trial database can help interested patients find a vaccine trial near them. For more updates on the fowlpox vaccine – including notifications when it advances to human studies – be sure to check back for future news posts.

Bertino, P. (4 February 2013.) Pietro Bertino, PhD., email interview with Asbestos.com. Bertino, P., Panigada, M., Soprana, E., Bianchi, V., Bertilaccio, S., Sanvito, F., … & Carbone, M. (2013). Fowlpox-based survivin vaccination for malignant mesothelioma therapy. International Journal of Cancer. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/ijc.28048/abstract American Thoracic Society. Possible vaccine for mesothelioma proven safe. (4 March 2010). Retrieved from http://www.eurekalert.org/pub_releases/2010-03/ats-pvf030210.php National Institutes of Health: A phase II trial to assess TroVax® plus chemotherapy in patients with malignant pleural mesothelioma (SKOPOS). (30 March 2012). Retrieved from http://clinicaltrials.gov/show/NCT01569919faith Faith Franz is a content writer for the Mesothelioma Center. She joined the team in January 2011 to help mesothelioma patients empower themselves through knowledge about their diagnosis. Twitter Facebook Reddit Delicious Stumbleupon

View the original article here